Provision Of Diabetes Wound Pads Based On Bacterial Cellulose With Impregnation Of Nanoencapsulation Andaliman (zanthoxylum Acanthopodium) Curcumin (curcuma Longa) As Anti -inflammatory And Antibacterial
Understanding the Challenge of Diabetes Wound Care
Diabetes mellitus is a chronic disease that often causes injury due to infection, caused by high levels of glucose in the blood. This condition creates a strategic environment for germ growth, so that the treatment of wounds in diabetics needs to be done immediately so that further complications can be prevented. According to the World Health Organization (WHO), diabetes is a major cause of morbidity and mortality worldwide, with an estimated 463 million adults living with diabetes in 2019. One effective solution in wound care is the use of wound pads that can control fluids from the wound and have antibacterial properties.
Innovative Approach with Bacterial Cellulose
In this study, bacterial cellulose modification was carried out through an impregnation process with the addition of nanoencapsulation andaliman (Zanthoxylum acanthopodium) and curcumin (curcuma longa). Both of these ingredients are expected to improve the ability of sanitary pads as antibacterial and anti-inflammatory. The use of nanoencapsulation technology has been shown to enhance the delivery of active ingredients, improving their efficacy and bioavailability. This impregnation process is carried out with a variation of andaliman and curcumin ratio, which is 1: 0, 1: 1, 1: 2, 1: 3, and 1: 4. The main focus of this study is to create an effective wound pads for diabetes mellitus wounds with nanoencapsulation variations in curcumin.
Research and Analysis Results
The test results using the Particle Size Analyzer showed that the size of the nanoencapsulation of andaliman and curcumin reached 0.03603 μm with an average of 0.02159 μm, which showed good potential for the drug delivery process. The use of particle size analysis is a crucial step in determining the efficacy of nanoencapsulation. Analysis using SEM and FTIR shows that the impregnation process goes well. From FTIR analysis, three absorption bands were found at 1690 cm-1, 2914 cm-1, and 3347 cm-1, which were also detected in the SB 1: 0 to SB 1: 4 spectrum ratio. FTIR analysis is a powerful tool for identifying the functional groups present in a material. The SEM results show that the SB fiber surface looks uneven and the number of lumps bound to the SB pores increases from the SB ratio of 1: 1 to 1: 4.
XRD analysis shows the success of ex-situ impregnation in the presence of two peaks at 11 ° and 22 °, which indicates that nanoencapsulation succeeded in fused with bacterial cellulose. XRD analysis is a useful technique for determining the crystallinity and structural properties of a material.
Antibacterial testing in the SB 1: 4 ratio shows the highest yield with a diameter of the inhibition zone of 12.3 mm to Staphylococcus aureus and 7 mm against Escherichia coli. The use of antibacterial testing is a crucial step in determining the efficacy of a wound pad. In addition, despite the water content and porosity of the nanoencapsulation andalcumin and the nanoencapsulation pads, this material can still meet the criteria as a wound pad.
Effectiveness in Wound Healing
One indicator of the success of this wound pad is its ability to closure diabetes wounds. In the SB 1: 4 ratio, the study showed the maximum results of the wound closure of 78.89% on the 17th day. The use of wound closure as an indicator of success is a common practice in wound care research.
Conclusion
In conclusion, wound pads developed through impregnation of nanoencapsulation andaliman and curcumin proved effective as material for diabetes mellitus wound care, by increasing antibacterial and anti-inflammatory properties, and supporting the process of healing wounds that are faster and more effective. This innovation can be an important breakthrough in health care for diabetics in the future. The use of nanoencapsulation technology has been shown to enhance the delivery of active ingredients, improving their efficacy and bioavailability. The results of this study demonstrate the potential of this technology in the development of effective wound pads for diabetes mellitus wounds.
Q: What is the main purpose of this study?
A: The main purpose of this study is to create an effective wound pad for diabetes mellitus wounds with nanoencapsulation variations in curcumin.
Q: What is the significance of using bacterial cellulose in wound care?
A: Bacterial cellulose is a biodegradable and non-toxic material that has been shown to have excellent wound healing properties. It is also highly absorbent, making it an ideal material for wound care.
Q: What is nanoencapsulation and how does it work?
A: Nanoencapsulation is a technology that involves encapsulating active ingredients in tiny particles, known as nanoparticles. These nanoparticles can be designed to release the active ingredients in a controlled manner, improving their efficacy and bioavailability.
Q: What are the benefits of using nanoencapsulation in wound care?
A: The use of nanoencapsulation in wound care has several benefits, including improved delivery of active ingredients, enhanced efficacy, and improved bioavailability.
Q: What are the antibacterial properties of the wound pad developed in this study?
A: The wound pad developed in this study has been shown to have excellent antibacterial properties, with a diameter of the inhibition zone of 12.3 mm to Staphylococcus aureus and 7 mm against Escherichia coli.
Q: How does the wound pad developed in this study support wound healing?
A: The wound pad developed in this study has been shown to support wound healing by increasing antibacterial and anti-inflammatory properties, and by promoting a faster and more effective healing process.
Q: What are the potential applications of this technology in wound care?
A: The technology developed in this study has the potential to be used in a variety of wound care applications, including the treatment of diabetic foot ulcers, pressure ulcers, and other types of wounds.
Q: What are the next steps in developing this technology?
A: The next steps in developing this technology include further testing and evaluation of the wound pad in clinical trials, as well as the development of larger-scale production methods.
Q: What are the potential benefits of this technology for patients with diabetes?
A: The technology developed in this study has the potential to provide patients with diabetes with a more effective and convenient treatment option for their wounds, which could improve their quality of life and reduce the risk of complications.
Q: What are the potential benefits of this technology for healthcare providers?
A: The technology developed in this study has the potential to provide healthcare providers with a more effective and convenient treatment option for their patients with diabetes, which could improve patient outcomes and reduce healthcare costs.